Max Gelman

New York

Senior Editor at Endpoints News

Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]

Featured in: Favicon

endpts.com Favicon

nydailynews.com Favicon

mlb.com

stltoday.com Favicon

pjstar.com Favicon

thepostgame.com Favicon

dailynorthwestern.com Favicon

amazinavenue.com Favicon

invesbrain.com

Articles

GSK, Spero report Phase 3 win for UTI antibiotic; Spero’s stock soars

1 week ago | endpts.com | Max Gelman

GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, setting up a potential FDA decision … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Liquidia wins approval for inhaled hypertension drug in two settings, furthering rivalry with United Therapeutics

1 week ago | endpts.com | Max Gelman

The FDA approved Liquidia’s treprostinil program for two related kinds of high blood pressure, turning up the heat on rival United Therapeutics and its Tyvaso … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

2 weeks ago | endpts.com | Max Gelman

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Roche confirms overall survival benefit for PI3K inhibitor in breast cancer

2 weeks ago | endpts.com | Max Gelman

The final overall survival results are in for Roche’s PI3K inhibitor, known as Itovebi, in certain forms of breast cancer. And they bode well for … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Jazz outlines full survival data for lung cancer drug Zepzelca

2 weeks ago | endpts.com | Max Gelman

A drug from Jazz Pharmaceuticals that has yet to read out confirmatory data in lung cancer succeeded in another Phase 3 trial, as the company … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Trump administration reveals ‘most favored nation’ drug price targets

2 weeks ago | endpts.com | Max Gelman

The Department of Health and Human Services provided the first details for how it plans to tie US drug prices to rates paid in similarly … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novo Nordisk CEO to step down, timeline for successor unknown

3 weeks ago | endpts.com | Max Gelman

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down, the company announced Friday morning. Novo has begun a search for Jørgensen’s successor, and Jørgensen will … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

3 weeks ago | endpts.com | Max Gelman

NEW YORK — Calley Means, a special White House employee and top advisor to HHS Secretary Robert F. Kennedy Jr., effectively dared Roche to pull its … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Bristol Myers CEO says America’s biopharma pole position is not guaranteed

3 weeks ago | endpts.com | Max Gelman

NEW YORK — Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a “pivot point” as the Trump administration … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

3 weeks ago | endpts.com | Max Gelman

The FDA approved a new antibody-drug conjugate from AbbVie on Wednesday to treat patients with certain kinds of lung cancer. Regulators granted accelerated approval to … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.